ALTG 14/002 NIVORAD: A randomised phase 2 trial of nivolumab and stereotactic ablative body radiotherapy in advanced non-small cell lung cancer progressing after first or second line chemotherapy – P Mitchell

NIVORAD is a trial to determine the activity and safety of combining nivolumab with local, palliative SABR to an extra-thoracic metastasis in patients with advanced NSCLC. The planned sample size is 120 at up to 25 ANZ sites and lead HREC approval was received in December 2015. Participating sites are currently completing local governance requirements. The trial was opened to recruitment in January 2017.

State/TerritorySitePIActivation DateEstimated Recruitment
NSWChris O'Brien LifehouseSteven Kao10
Prince of Wales HospitalCraig Lewis8
Royal North Shore HospitalNick Pavlakis6 Jan 201710
Sydney Adventist HospitalCsilla Hasovits5
The Tweed HospitalEhtesham Abdi8
QLDGenesis Cancer CareKen O'Byrne6
Nambour General Hospital (Sunshine Coast Health Service District)Kathleen Houston6
Princess Alexandra HospitalKen O'Byrne20
Royal Brisbane and Women's HospitalBrett Hughes15 Feb 201710
Townsville HospitalSuresh Varma6 Jan 201710
SAFlinders Medical CentreChris Karapetis15
Royal Adelaide HospitalHien Le20 Feb 201710
TASRoyal Hobart HospitalLouise Nott6
VICAustin HospitalPaul Mitchell18
Peninsula South Eastern Haematology & Oncology GroupVinod Ganju6
St Vincent's HospitalSue-Anne McLachlan6
Western Health Sunshine/Western Health Lung Oncology (Footscray)Shankar Siva22 Feb 201710
WASir Charles Gairdner HospitalArman Hasani4
Other (NZ)Auckland City Hospital - Auckland District Health BoardGeorge Laking6

Study Contacts

Study Chair: Paul Mitchell

CTC Trial Coordinator: Annie Yeung

Upcoming Events
  1. ***UPDATED*** ALTG Members’ Meeting, Sydney NSW

    November 24
  2. ***UPDATED*** Shine A Light Dinner, Sydney NSW

    November 24 @ 6:00 pm - 9:00 pm AEST
  3. ***UPDATED*** 2017 ALTG Lung Cancer Symposium, Sydney NSW

    November 25 @ 9:00 am - 5:00 pm UTC+10